Himmel Pharmaceuticals Private Limited
Private pharmaceutical company · Lahore · Pakistan
Lahore specialty pharmaceutical company focused on branded medicines in oncology, haematology, cardiology, radiology and general medicine.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical company
- Address
- Ground Floor, 6 Judicial Colony, Phase 1 Extension, Shahrah Nazaria-e-Pakistan, Lahore, Pakistan
- Website
- himmelpharma.pk ↗
- Phone
- +92 42 35307272
- info@himmelpharma.pk
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Abiteron | Abiraterone acetate | 250 mg | Tablet | 120's | 110488 | PKR 202,094.93 | PKR 1,684.12/tablet | Near median |
| Afanix | Afatinib | 40 mg | Tablet | 3*10's | 114223 | PKR 55,103.15 | PKR 1,836.77/tablet | No comparator |
| Bortezomib | Bortezomib | 3.5 mg/1.4 mL | Solution for injection | 1's | 115748 | PKR 45,241.34 | PKR 45,241.34/vial/unit | No comparator |
| Bortezomib Pharmidea | Bortezomib | 3.5 mg | Powder for solution for IV injection | 1's | 093929 | PKR 45,241.34 | PKR 45,241.34/vial/unit | No comparator |
| Bortezomib Pharmidea | Bortezomib | 3.5 mg | IV injection | 1's | 093929 | PKR 45,241.34 | PKR 45,241.34/vial/unit | No comparator |
| Carplatu | Carboplatin | 150 mg/15 mL | Solution for IV infusion | 1's | 097370 | PKR 4,319.81 | PKR 4,319.81/vial/unit | No comparator |
| Carplatu | Carboplatin | 150 mg/15 mL | Solution for infusion | 1's | 097370 | PKR 4,319.81 | PKR 4,319.81/vial/unit | No comparator |
| Carplatu | Carboplatin | 450 mg/45 mL | Solution for infusion | 1's | 097371 | PKR 8,639.65 | PKR 8,639.65/vial/unit | No comparator |
| Casomid 50mg Film Coated | Bicalutamide | 50 mg | Tablet | 28's | 097366 | PKR 6,390.05 | PKR 228.22/tablet | Near median |
| Cipintu | Cisplatin | 50 mg/50 mL | Concentrate for solution for infusion | 1's | 099486 | PKR 2,421.05 | PKR 2,421.05/vial/unit | No comparator |
| Cipintu | Cisplatin | 50 mg/50 mL | Concentrate for infusion | 1's | 099486 | PKR 2,421.05 | PKR 2,421.05/vial/unit | No comparator |
| Docetaxel AqVida | Docetaxel | 20 mg | IV infusion | 1's | 084811 | PKR 12,826.25 | PKR 12,826.25/vial/unit | No comparator |
| Docetaxel AqVida | Docetaxel | 80 mg/4 mL | Concentrate for solution for IV infusion | 1's | 084812 | PKR 31,598.91 | PKR 31,598.91/vial/unit | No comparator |
| Docetaxel AqVida | Docetaxel | 80 mg/4 mL | IV infusion | 1's | 084812 | PKR 31,598.91 | PKR 31,598.91/vial/unit | No comparator |
| DoxoOnko | Doxorubicin | 10 mg/5 mL | Concentrate for infusion | 1's | 099019 | PKR 809.54 | PKR 809.54/vial/unit | No comparator |
| DoxoOnko | Doxorubicin | 50 mg/25 mL | Concentrate for solution for IV infusion / intravesical use | 1's | 099020 | PKR 2,765.98 | PKR 2,765.98/vial/unit | No comparator |
| DoxoOnko | Doxorubicin | 50 mg/25 mL | Concentrate for infusion | 1's | 099020 | PKR 2,765.98 | PKR 2,765.98/vial/unit | No comparator |
| Enox | Enoxaparin | 4000 anti-Xa IU/0.4 mL | Prefilled syringe injection | 10's | 120497 | PKR 8,805.39 | PKR 880.54/syringe | No comparator |
| Enox 2000 Anti-Xa IU | Enoxaparin | 2000 IU/0.2 mL | Prefilled syringe injection | 2's | 120496 | PKR 1,100.21 | PKR 550.11/syringe | Near median |
| Enox 4000 Anti-Xa IU | Enoxaparin | 4000 IU/0.4 mL | Prefilled syringe injection | 2's | 120497 | PKR 1,834.46 | PKR 917.23/syringe | Near median |
| Enox 6000 Anti-Xa IU | Enoxaparin | 6000 IU/0.6 mL | Prefilled syringe injection | 2's | 120498 | PKR 2,877.92 | PKR 1,438.96/syringe | Near median |
| Enox 8000 Anti-Xa IU | Enoxaparin | 8000 IU/0.8 mL | Prefilled syringe injection | 2's | 120499 | PKR 3,372.43 | PKR 1,686.22/syringe | Near median |
| Everose 10mg TabletRegistry verified | Everolimus | — | — | — | 128934Official source ↗ | No indexed price | — | — |
| Everose 5mg TabletRegistry verified | Everolimus | — | — | — | 128933Official source ↗ | No indexed price | — | — |
| Himrox 250mg Dispersible | Deferasirox | 250 mg | Tablet | 30's | 097368 | PKR 7,514.80 | PKR 250.49/tablet | 20% below median |
| Himrox 250mg Dispersible | Deferasirox | 250 mg | Dispersible tablet | 28's | 097368 | PKR 7,013.81 | PKR 250.49/tablet | 29% below median |
| Himrox 500mg Dispersible | Deferasirox | 500 mg | Tablet | 30's | 097369 | PKR 12,524.67 | PKR 417.49/tablet | 21% below median |
| Himrox 500mg Dispersible | Deferasirox | 500 mg | Dispersible tablet | 28's | 097369 | PKR 11,689.69 | PKR 417.49/tablet | 12% below median |
| HimTam | Tamoxifen | 20 mg | Tablet | 30's | 099484 | PKR 816.19 | PKR 27.21/tablet | Near median |
| HimTam | Tamoxifen | 20 mg | Tablet | 2x30's | 099484 | PKR 1,390.56 | PKR 23.18/tablet | 18% below median |
| Ibrutix | Ibrutinib | 140 mg | Capsule | 120's | 114232 | PKR 248,207.37 | PKR 2,068.39/capsule | Near median |
| Irinotecan HCl AqVida | Irinotecan | 100 mg | Concentrate for solution for infusion | 1's | 114235 | PKR 13,833.19 | PKR 13,833.19/vial/unit | 47% below median |
| Irinotecan HCl AqVida | Irinotecan | 100 mg | Solution for infusion | 1's | 114235 | PKR 13,833.19 | PKR 13,833.19/vial/unit | No comparator |
| Leugon | Leuprorelin acetate | 11.25 mg | Implant | 1's | 110487 | PKR 43,371.39 | PKR 43,371.39/unit | No comparator |
| Linamide | Lenalidomide | 10 mg | Capsule | 21's | 099497 | PKR 15,967.22 | PKR 760.34/capsule | Near median |
| Linamide | Lenalidomide | 10 mg | Capsule | 18's | 099497 | PKR 13,686.19 | PKR 760.34/capsule | Near median |
| Linamide | Lenalidomide | 25 mg | Capsule | 21's | 099498 | PKR 35,225.44 | PKR 1,677.40/capsule | Near median |
| Linamide | Lenalidomide | 25 mg | Capsule | 18's | 099498 | PKR 30,146.91 | PKR 1,674.83/capsule | Near median |
| Nab-Xelpac | Paclitaxel | 100 mg | Injection | 1's | 106640 | PKR 53,560.73 | PKR 53,560.73/vial/unit | 112% above median |
| Nab-Xelpac | Paclitaxel (albumin-bound nanoparticles) | 100 mg | Injection | 1's | 106640 | PKR 53,560.73 | PKR 53,560.73/vial/unit | 151% above median |
| Nanogam | Human normal immunoglobulin (IgG) | 2.5 g/50 mL | Solution for infusion | 1's | 111121 | PKR 27,086.53 | PKR 27,086.53/vial/unit | No comparator |
| Nanogam | Human normal immunoglobulin (IgG) | 5 g/100 mL | Solution for infusion | 1's | 111122 | PKR 45,143.27 | PKR 45,143.27/vial/unit | No comparator |
| Nanogam | Human normal immunoglobulin (IgG) | 10 g/200 mL | Solution for infusion | 1's | 115152 | PKR 71,293.39 | PKR 71,293.39/vial/unit | No comparator |
| Nilonix | Nilotinib | 150 mg | Capsule | 120's | 110539 | PKR 280,822.42 | PKR 2,340.19/capsule | Near median |
| Nilonix | Nilotinib | 200 mg | Capsule | 120's | 110540 | PKR 372,767.98 | PKR 3,106.40/capsule | Near median |
| Nilonix | Nilotinib | 200 mg | Capsule | 112's | 110540 | PKR 349,468.04 | PKR 3,120.25/capsule | Near median |
| Norevell | Sevoflurane | 100% | Inhalation liquid | 250ml | 115770 | PKR 11,022.70 | PKR 44.09/mL | 12% below median |
| Oxaliplatin | Oxaliplatin | 100 mg/20 mL | IV infusion | 1's | 084810 | PKR 38,829.99 | PKR 38,829.99/vial/unit | No comparator |
| Oxaliplatin | Oxaliplatin | 50 mg/10 mL | IV infusion | 1's | 085251 | PKR 19,414.99 | PKR 19,414.99/vial/unit | No comparator |
| Paclitaxel AqVida | Paclitaxel | 300 mg/50 mL | IV infusion | 1's | 084630 | PKR 39,460.98 | PKR 39,460.98/vial/unit | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.